School of Public Health, University at Albany, State University of New York, Albany, NY.
School of Public Health, University at Albany, State University of New York, Albany, NY.
J Thorac Cardiovasc Surg. 2019 Apr;157(4):1432-1439.e2. doi: 10.1016/j.jtcvs.2018.08.091. Epub 2018 Sep 26.
The purposes of this study are to compare outcomes of mitral valve repair (MV-repair) and mitral valve replacement for patients with severe mitral regurgitation with preserved ventricular function and no congestive heart failure (CHF) symptoms and to examine variations in surgeon choice of procedure and outcomes by surgeon volume.
In total, 2259 consecutive patients in 42 New York State hospitals with the characteristics mentioned previously who underwent mitral valve repair (1801, 79.7%) or replacement between January 1, 2008, and December 31, 2014, were identified from a mandatory statewide clinical registry. Propensity-matching was used to compare mortality and competing risk analyses were used to compare nonfatal outcomes. Median follow-up was 4.0 years. The use of mitral repair and risk-adjusted mortality for surgery were also examined as a function of individual surgeon mitral case volume.
Propensity-matched patients who underwent MV-repair experienced a significantly lower mortality rate at 4 years (3.5% vs 12.1%, P < .001). Greater-volume surgeons were more likely to perform MV-repairs (92% vs 84%, 74%, and 69% in lower volume quartiles, respectively). No significant differences in mortality were observed among volume quartiles.
Patients with chronic severe primary mitral valve regurgitation with preserved ventricular function and no CHF symptoms who underwent MV-repair experienced lower mortality and no different reoperation, CHF, or stroke readmission rates than patients who underwent replacement. Greater-volume surgeons were more likely than their lower volume counterparts to choose mitral repair. Repair should be considered as the surgical option for these patients whenever possible.
本研究旨在比较伴有射血分数保留且无充血性心力衰竭(CHF)症状的慢性重度原发性二尖瓣反流患者行二尖瓣修复(MV-修复)和二尖瓣置换术的结局,并通过外科医生手术量来检验手术方式选择和结局的差异。
总共纳入了 42 家纽约州医院的 2259 例具有上述特征的连续患者,这些患者于 2008 年 1 月 1 日至 2014 年 12 月 31 日期间接受了二尖瓣修复(1801 例,79.7%)或置换术。使用倾向评分匹配比较死亡率,使用竞争风险分析比较非致死性结局。中位随访时间为 4.0 年。还考察了每位外科医生二尖瓣手术量对二尖瓣修复的使用和风险调整后手术死亡率的影响。
接受 MV-修复的患者在 4 年时的死亡率明显较低(3.5% vs. 12.1%,P < 0.001)。手术量较大的外科医生更倾向于行 MV-修复(92% vs. 84%、74%和 69%,分别在较低的四分位数中)。在四分位数之间未观察到死亡率存在显著差异。
对于伴有射血分数保留且无 CHF 症状的慢性重度原发性二尖瓣反流患者,接受 MV-修复的患者死亡率较低,且与接受置换术的患者相比,再次手术、CHF 或中风再入院的发生率无差异。手术量较大的外科医生比手术量较小的医生更倾向于选择二尖瓣修复术。只要有可能,修复术都应作为这些患者的手术选择。